Eupraxia's EoE Drug Shows Strong Symptom Reduction in Phase 1b/2a Trial
Event summary
- Eupraxia reported 24-week symptom data from the highest dose cohort in its Phase 1b/2a RESOLVE trial for eosinophilic esophagitis (EoE), showing a 4-point average reduction in SDI scores.
- 76% of patients in cohorts 4-9 maintained clinical remission at 24 weeks, with no serious adverse events reported across 31 patients and 220 patient-months of follow-up.
- The trial introduced a new 6 mg/site cohort (Cohort 8b) with improved drug delivery using larger catheters, showing significantly better outcomes compared to the original 6 mg/site cohort.
- Phase 2b of the RESOLVE trial is currently recruiting, with top-line data expected in Q3 2026.
The big picture
Eupraxia's Diffusphere™ technology aims to revolutionize local drug delivery by providing controlled, extended-release formulations. The positive Phase 1b/2a data for EP-104GI in EoE positions the company as a potential disruptor in the treatment of inflammatory gastrointestinal diseases, addressing a significant unmet medical need. The trial's success could pave the way for broader applications of the Diffusphere™ platform in other therapeutic areas, including oncology and infectious diseases.
What we're watching
- Clinical Efficacy
- Whether the sustained symptom reduction observed in the highest dose cohort will translate into successful outcomes in the placebo-controlled Phase 2b trial.
- Drug Delivery Optimization
- The impact of the improved catheter design on drug delivery efficiency and patient outcomes in future cohorts.
- Regulatory Pathway
- The pace at which Eupraxia can advance EP-104GI through regulatory approvals given the positive interim data.
Related topics